BJDX · Bluejay Diagnostics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | $249.0K | - |
| Cost of Revenue | - | - | - | $200.1K | - |
| Gross Profit | - | - | - | $48.9K | - |
| R&D | $3.05M | $3.47M | $5.71M | $4.15M | $527.3K |
| SG&A | $3.91M | $3.69M | $451.4K | $4.76M | $596.1K |
| Total Operating Expenses | $6.95M | $7.17M | $10.31M | $9.37M | $1.20M |
| D&A | $74.2K | $75.6K | $648.7K | $156.6K | $157.0K |
| Operating Income | ($6.95M) | ($7.17M) | ($10.31M) | ($9.32M) | ($1.20M) |
| Interest Expense | $839 | $823.0K | - | $6.4K | $59.3K |
| Income Tax | - | - | - | - | - |
| Net Income | ($6.85M) | ($7.72M) | ($9.95M) | ($9.30M) | ($1.16M) |
| EPS - Basic | ($15.25) | ($456.76) | ($14528.00) | ($14720.00) | - |
| EPS - Diluted | ($15.25) | ($456.76) | ($14528.00) | ($13120.00) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $5.16M | $4.30M | $2.21M | $10.11M | $19.05M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $214.3K | $145.1K | $491.5K | $635.8K | $295.8K |
| Current Assets | $5.46M | $4.90M | $3.22M | $11.79M | $20.66M |
| Total Assets | $7.12M | $6.66M | $4.87M | $13.52M | $21.02M |
| Current Liabilities | $1.12M | $810.4K | $1.77M | $1.64M | - |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $1.14M | $927.9K | $1.97M | $1.98M | $637.2K |
| Stockholders' Equity | $5.98M | $5.73M | $2.89M | $11.54M | $20.38M |
| Retained Earnings | ($41.52M) | ($34.67M) | ($26.95M) | ($17.00M) | ($7.69M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($6.05M) | ($7.82M) | ($8.31M) | ($7.74M) | ($508.7K) |
| Investing Cash Flow | ($173.7K) | ($306.8K) | ($704.2K) | ($1.20M) | ($23.9K) |
| Financing Cash Flow | $7.09M | $10.22M | $1.11M | $8.1K | $1.33M |
| CapEx | $173.7K | $306.8K | $704.2K | $1.20M | $23.9K |
| Free Cash Flow | ($6.23M) | ($8.13M) | ($9.02M) | ($8.94M) | ($532.7K) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | 19.6% | - |
| Operating margin | - | - | - | -3741.5% | - |
| EBITDA margin | - | - | - | -3678.6% | - |
| Net margin | - | - | - | -3733.1% | - |
| Free cash flow margin | - | - | - | -3590.1% | - |
| FCF / Net income | 0.91 | 1.05 | 0.91 | 0.96 | 0.46 |
| R&D / Revenue | - | - | - | 1667.3% | - |
| SG&A / Revenue | - | - | - | 1912.6% | - |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -96.2% | -115.9% | -204.5% | -68.8% | -5.5% |
| Return on equity | -114.6% | -134.7% | -343.8% | -80.6% | -5.7% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 4.88 | 6.05 | 1.82 | 7.19 | - |
| Quick ratio | 4.88 | 6.05 | 1.82 | 7.19 | - |
| Cash ratio | 4.61 | 5.31 | 1.25 | 6.17 | - |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | -8287.2x | -8.7x | - | -1465.1x | -20.2x |
| Equity multiplier | 1.19 | 1.16 | 1.68 | 1.17 | 1.03 |
| Liabilities / Assets | 0.16 | 0.14 | 0.41 | 0.15 | 0.03 |
| Efficiency | |||||
| Asset turnover | - | - | - | 0.02 | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | 1160d | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | 0.2x | 0.6x | 739.4x | 21244.9x | - |
| P / S | - | - | - | 984553.5x | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | 3.0% | 30.5% | -10.7% | -678.8% | - |
| Net income growth (YoY) | 11.3% | 22.5% | -7.1% | -702.6% | - |
| EPS growth (YoY) | 96.7% | 96.9% | -10.7% | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | 23.4% | 9.9% | -0.9% | -1578.5% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | 4.3% | 97.9% | -74.9% | -43.4% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Bluejay Diagnostics against the 5 most active filers in the same SIC group.